Liangsu Wang,

Vice President, Scientific Innovation, Cardiovascular & Metabolism

Liangsu is Vice President, Scientific Innovation, Cardiovascular & Metabolism (CVM) at Johnson & Johnson Innovation, California. In this role, she is responsible for creating and implementing the company’s CVM therapeutic area’s external innovation partnership strategy and portfolio, and to identify opportunities from academia and external companies in West North America, Australia and New Zealand.

Liangsu brings 25 years of experience in large pharma and small biotech companies with expertise spanning drug discovery through clinical development in multiple disease areas. She joins Johnson & Johnson Innovation from her previous role as Vice President, Head of Biology for biotech start-up, Morphic Therapeutic, where she spearheaded the building of a robust drug discovery portfolio focused on fibrosis, autoimmunity, immuno-oncology, intestinal fibrostenosis and PAH. Prior to her time at Morphic Therapeutic, she spent nearly 13 years at Merck, working across a range of cardiometabolic, cardiovascular and infectious diseases developing a track record for establishing and leading collaborations with partners in academia and industry. She served as the Executive Director, Department Head for Diabetes & NASH Late Discovery, accountable for the Diabetes and NASH drug discovery portfolio as well as discovery support of clinical development programs. Prior to joining Merck, Liangsu spent eight years in biotech companies in San Diego.

Liangsu received her B.Sc. in Genetics and Genetic Engineering from Fudan University in China, followed by her Ph.D. in Biochemistry and Molecular Biology from the University of Calgary, Canada. She has also been trained in in Bioinformatics and Computational Biology, published more than 30 papers and holds three patents.

Liangsu Wang
Liangsu Wang